ポスト

The FDA has granted fast track designation to the investigational TOPO1i anti-Claudin 18.2 antibody drug conjugate IBI343 as a treatment for patients with advanced unresectable or metastatic pancreatic ductal adenocarcinoma. #pancsm https://t.co/koJqZ0gcy7

メニューを開く

CancerNetwork®@CancerNetwrk

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ